Ironwood Scoops Up Gastrointestinal Diseases Player For $1B
Portfolio Pulse from Vandana Singh
Ironwood Pharmaceuticals has agreed to acquire VectivBio Holding for $17.00 per share in an all-cash transaction worth approximately $1 billion. The acquisition can potentially strengthen Ironwood's portfolio and pipeline to advance the treatment of gastrointestinal diseases. Ironwood expects the deal to be accretive to earnings per share beginning in 2026.
May 22, 2023 | 6:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ironwood Pharmaceuticals acquires VectivBio for $1B, potentially strengthening its portfolio and pipeline for gastrointestinal disease treatments.
The acquisition of VectivBio is expected to strengthen Ironwood's portfolio and pipeline for gastrointestinal disease treatments. This could lead to increased revenue and growth for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
VectivBio has been acquired by Ironwood Pharmaceuticals for $17.00 per share in an all-cash transaction worth approximately $1 billion.
The acquisition of VectivBio by Ironwood Pharmaceuticals at a premium price of $17.00 per share represents a significant gain for VectivBio shareholders. This is likely to have a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100